BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Minerva Biotechnologies Corporation Looks for New CEO


2/1/2008 7:02:48 AM

WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies announced today that it will be recruiting a new CEO following the board of director’s termination of its past CEO, Jim Czirr. At the same time, the Company has initiated legal proceedings against Mr. Czirr in Massachusetts Superior Court.

Minerva Biotechnologies was founded in 1999 by Dr. Cynthia Bamdad (inventor of the universal DNA chip & protein chip) to develop “next generation” biochips: affinity nanoparticles. Minerva enjoys a broad and dominant intellectual property position in the field of nanotechnology with over 100 patent applications filed with US and worldwide rights reserved. Minerva’s intellectual property covers a wide range of uses for its nanoparticle systems in fields as diverse as drug discovery, proteomics, opto-electronics and nano-scale biosensors. It has utilized its nanoparticle technology to develop protein and small molecule drugs against human tumor stem cell antigens, and is developing several novel cancer therapies for breast cancer and lung cancer.

For more information, visit www.MinervaBio.com or call (781) 487-0200 X101.

Copyright © 2008, Minerva Biotechnologies, Corp. All rights reserved.

Contact: Minerva Biotechnologies, Corp. Dr. Cynthia Bamdad, 781-487-0200 X101 cbamdad@minervabio.com

Source: Minerva Biotechnologies, Corp.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES